Rivastigmine Tartrate Capsule
Product Images NDC 72241-011

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Rivastigmine Tartrate (NDC 72241-011). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Modavar Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fig1 (Rivastigmine Spl Fig1)

A line graph displaying mean change from baseline in ADAS-cog rating over 26 weeks of treatment. It compares clinical improvement and decline among three groups: 6-12 mg, 1-4 mg, and placebo doses, with values plotted at 0, 12, 18, and 26 weeks. Error bars show SEM variability.*

FDA Label Image

Fig2 (Rivastigmine Spl Fig2)

A cumulative distribution plot showing the percentage of patients versus change from baseline in the ADAS-cog score. It compares three groups: 6-12 mg treatment, 1-4 mg treatment, and placebo, with markers representing each group. The plot highlights threshold changes at -7 points, -4 points, and no change, alongside a table summarizing the mean changes for each group.*

FDA Label Image

Fig3 (Rivastigmine Spl Fig3)

A bar chart showing patient percentage distribution across seven CIBIC-Plus rating categories: Markedly Improved, Moderately Improved, Minimally Improved, Unchanged, Minimally Worse, Moderately Worse, and Markedly Worse. Data compare three groups: Placebo, 1-4 mg, and 6-12 mg dosages, with highest percentages in the Unchanged category for all groups.*

FDA Label Image

Rivastigmine-spl-fig4 (Rivastigmine Spl Fig4)

A line graph showing mean change from baseline ADAS-cog rating over weeks during treatment for three groups: 6-12 mg, 1-4 mg, and placebo. The y-axis ranges from clinical improvement to clinical decline, with data points and error bars indicating changes at multiple time points up to 26 weeks.*

FDA Label Image

Fig5 (Rivastigmine Spl Fig5)

A cumulative percentage of patients chart showing change from baseline on the X-axis (ranging approximately from -25 to 30) and cumulative percentage on the Y-axis (0 to 100%). The graph compares treatment groups including 6-12 mg, 1-4 mg, and placebo, with corresponding curves. An inset table details changes in ADAS-cog scores for treatment groups and placebo at different dosages.*

FDA Label Image

Fig6 (Rivastigmine Spl Fig6)

A bar chart showing the distribution of patients' CIBIC-Plus ratings across seven categories from Markedly Improved to Markly Worse, comparing three groups: Placebo, 1-4 mg, and 6-12 mg. The vertical axis represents the percentage of patients, and the chart visually compares the effect of different dosages and placebo on patient outcomes.*

FDA Label Image

Fig7 (Rivastigmine Spl Fig7)

A line graph showing clinical improvement and decline over 24 weeks during treatment. The x-axis represents weeks during treatment (0, 8, 16, 24), and the y-axis shows the mean change from baseline in ADAS-cog rating. Two lines compare Exelon and placebo groups, with Exelon showing clinical improvement and placebo near baseline or decline.*

FDA Label Image

Fig8 (Rivastigmine Spl Fig8)

Bar chart comparing the percentage of patients rated on the ADCS-CGIC scale between Exelon and Placebo groups. The x-axis shows categories from Markedly Improved to Markedly Worse, while the y-axis indicates percentage of patients. Bars for both Exelon and Placebo are shown side-by-side across the categories.*

FDA Label Image

Rivastigmine-spl-label-60cap-1-5mg.jpg (Rivastigmine Spl Label 60cap 1 5mg)

Label for Rivastigmine Tartrate Capsules USP 1.5 mg by Modavar Pharmaceuticals. The label shows the NDC 72241-011-03 and indicates a bottle containing 60 capsules. Manufacturer details are Cadila Pharmaceuticals Ltd. in India, with labeling for Modavar Pharmaceuticals LLC in Washington, DC. The label includes storage instructions, dosage reference to prescribing info, and a barcode. There is a marked space for serialization, datamatrix, code, and batch coding.*

FDA Label Image

Rivastigmine-spl-label-60cap-3mg.jpg (Rivastigmine Spl Label 60cap 3mg)

Rivastigmine Tartrate Capsules USP 3 mg label showing drug strength, quantity of 60 capsules, and Rx only designation. The label includes manufacturer details from Cadila Pharmaceuticals Ltd., India, and Modavar Pharmaceuticals LLC, Washington, DC. Storage instructions, barcode, and issuance date 06/2021 are also visible, along with unidentified batch coding area.*

FDA Label Image

Rivastigmine-spl-label-60cap-4-5mg.jpg (Rivastigmine Spl Label 60cap 4 5mg)

The label of Rivastigmine Tartrate Capsules USP 4.5 mg by Modavar Pharmaceuticals features the product name, strength, and dosage form. It indicates a 60-capsule package, manufacturing details by Cadila Pharmaceuticals Ltd. in India, and labeling by Modavar Pharmaceuticals LLC in the U.S. A barcode and storage instructions are also shown.*

FDA Label Image

Rivastigmine-spl-label-60cap-6mg (Rivastigmine Spl Label 60cap 6mg)

Rivastigmine Tartrate Capsules USP 6 mg packaging label showing the dosage strength and count of 60 capsules. The label includes manufacturer details for Cadila Pharmaceuticals Ltd. in India and Modavar Pharmaceuticals LLC in Washington, DC. It also lists storage instructions and references prescribing information for dosage and administration.*

FDA Label Image

Str (Rivastigmine Spl Structure)

Chemical structure diagram of Rivastigmine Tartrate, a human prescription drug used in oral capsule form. The structure shows molecular components including aromatic and nitrogen groups with tartrate indicated by C4H6O6.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.